Patients with pollen-related allergic rhinitis prefer on demand antihistamines, with treatment preferences differing markedly ...
Allergic rhinitis shows dual effects on COVID 19 symptoms, while sublingual immunotherapy modifies respiratory and fever risk ...
The AIM-listed immunotherapy specialist will present three posters at the AAAAI Annual Meeting in Philadelphia this week ...
Recent research has revealed that allergic rhinitis (AR) can significantly influence COVID-19 symptom patterns, showing both protective and risk associations, while sublingual immunotherapy (SLIT) ...
According to MarketsandMarkets™, the Allergy Diagnostics Market is projected to grow from about USD 6.80 billion in 2026 to ...
New research reveals key childhood food allergy risk factors, from eczema to delayed allergen introduction. Discover what clinicians should watch for.
By type, the subcutaneous immunotherapy segment held the highest share in the year 2023. Subcutaneous immunotherapy helps reduce allergy symptoms. It is known to offer sustained relief even after ...
Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy ...
Altamira Medica’s Bentrio nasal spray receives notice of allowance from Japan Patent Office: Hamilton, Bermuda Monday, February 16, 2026, 16:00 Hrs [IST] Altamira Therapeutics L ...
Neurent Medical today announced positive findings from a randomized controlled trial evaluating its Neuromark system.
Montelukast is a leukotriene receptor antagonist approved for the prophylactic and chronic treatment of asthma and the relief of allergic rhinitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results